260,200 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 260,200 shares of the biotechnology company’s stock, valued at approximately $2,909,000.

A number of other large investors also recently bought and sold shares of ADMA. Quest Partners LLC bought a new position in ADMA Biologics during the 2nd quarter valued at $29,000. EntryPoint Capital LLC acquired a new stake in shares of ADMA Biologics in the first quarter valued at $31,000. CWM LLC boosted its stake in ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares in the last quarter. Acadian Asset Management LLC acquired a new position in ADMA Biologics during the second quarter worth about $93,000. Finally, Viewpoint Capital Management LLC raised its position in ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock opened at $19.44 on Friday. ADMA Biologics, Inc. has a one year low of $3.06 and a one year high of $20.16. The firm has a 50-day moving average of $16.27 and a two-hundred day moving average of $11.30. The firm has a market capitalization of $4.51 billion, a PE ratio of -972.00 and a beta of 0.61. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the prior year, the firm earned ($0.02) EPS. The firm’s quarterly revenue was up 78.4% on a year-over-year basis. On average, analysts forecast that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock valued at $8,224,121 over the last quarter. Company insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ADMA. Mizuho raised their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright upped their price target on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and an average target price of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.